| dc.contributor |
Médecins Sans Frontières Aral Sea Area Programme, Uzbekistan and Turkmenistan, Tashkent, Uzbekistan. hom@msfh-tashkent.uz |
|
| dc.creator |
Cox, H |
|
| dc.creator |
Orozco, J D |
|
| dc.creator |
Male, R |
|
| dc.creator |
Ruesch-Gerdes, S |
|
| dc.creator |
Falzon, D |
|
| dc.creator |
Small, I |
|
| dc.creator |
Doshetov, D |
|
| dc.creator |
Kebede, Y |
|
| dc.creator |
Aziz, M |
|
| dc.date |
2004-05 |
|
| dc.date.accessioned |
2017-01-31T07:09:35Z |
|
| dc.date.available |
2017-01-31T07:09:35Z |
|
| dc.identifier |
Multidrug-Resistant Tuberculosis in Central Asia. 2004, 10 (5):865-72 Emerging Infect. Dis. |
|
| dc.identifier |
1080-6040 |
|
| dc.identifier |
15200821 |
|
| dc.identifier |
http://hdl.handle.net/10144/17739 |
|
| dc.identifier |
http://fieldresearch.msf.org/msf/handle/10144/17739 |
|
| dc.identifier |
Emerging Infectious Diseases |
|
| dc.identifier.uri |
http://dspace.mediu.edu.my:8181/xmlui/handle/10144/17739 |
|
| dc.description |
Multidrug-resistant tuberculosis (MDR-TB) has emerged as a major threat to TB control, particularly in the former Soviet Union. To determine levels of drug resistance within a directly observed treatment strategy (DOTS) program supported by Médecins Sans Frontières in two regions in Uzbekistan and Turkmenistan, Central Asia, we conducted a cross-sectional survey of smear-positive TB patients in selected districts of Karakalpakstan (Uzbekistan) and Dashoguz (Turkmenistan). High levels of MDR-TB were found in both regions. In Karakalpakstan, 14 (13%) of 106 new patients were infected with MDR-TB; 43 (40%) of 107 previously treated patients were similarly infected. The proportions for Dashoguz were 4% (4/105 patients) and 18% (18/98 patients), respectively. Overall, 27% of patients with positive smear results whose infections were treated through the DOTS program in Karakalpakstan and 11% of similar patients in Dashoguz were infected with multidrug-resistant strains of TB on admission. These results show the need for concerted action by the international community to contain transmission and reduce the effects of MDR-TB. |
|
| dc.language |
en |
|
| dc.relation |
http://www.cdc.gov/ncidod/eid |
|
| dc.rights |
Archived on this site by permission of CDC |
|
| dc.title |
Multidrug-Resistant Tuberculosis in Central Asia. |
|